References
- SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin20156552925559415
- ChenWZhengRZengHZhangSHeJAnnual report on status of cancer in China, 2011Chin J Cancer Res20152721225717220
- CisykALPenner-GoekeSLichtensztejnZCharacterizing the prevalence of chromosome instability in interval colorectal cancerNeoplasia20151730631625810015
- KrausSNabiochtchikovIShapiraSArberNRecent advances in personalized colorectal cancer researchCancer Lett2014347152124491406
- LiaoMWangGQuanBAnalyzing large-scale samples confirms the association between rs16892766 polymorphism and colorectal cancer susceptibilitySci Rep20155795725609216
- WuZJiangPZulqarnainHGaoHZhangWRelationship between single-nucleotide polymorphism of matrix metalloproteinase-2 gene and colorectal cancer and gastric cancer susceptibility: a meta-analysisOnco Targets Ther2015886186925945057
- KranenburgOThe KRAS oncogene: past, present, and futureBiochim Biophys Acta20051756818216269215
- SuJZhangXCAnSJDetecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assayChin J Cancer20143334635024823994
- Oczko-WojciechowskaMPfeiferARusinekDThe prevalence of somatic RAS mutations in medullary thyroid cancer – a Polish population studyEndokrynol Pol20156612112525931041
- SmithGBoundsRWolfHSteeleRJCareyFAWolfCRActivating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicineBr J Cancer201010269370320147967
- SakaiKTsurutaniJYamanakaTExtended RAS and BRAF mutation analysis using next-generation sequencingPLoS One201510e012189125954997
- YingHQWangFHeBSThe involvement of Kras gene 3′-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysisOnco Targets Ther201471487149625210463
- IshigeTItogaSSatoKHigh-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinomaClin Biochem20144734034325262986
- BlonsHEmileJFLe MalicotKPrognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetAnn Oncol2014252378238525294886
- DienstmannRSalazarRTaberneroJPersonalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patientsJ Clin Oncol2015331787179625918287
- RoushSSlackFJThe let-7 family of microRNAsTrends Cell Biol20081850551618774294
- SaridakiZWeidhaasJBLenzHJA let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapyClin Cancer Res2014204499451025183481
- WangWYChienYCWongYKLinYLLinJCEffects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinomaHead Neck20123466366621688344
- JinHLiangYWangXAssociation between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancerMed Oncol20143122125201577
- PeakallRSmousePEGenAlEx 6.5: genetic analysis in excel. Population genetic software for teaching and research – an updateBioinformatics2012282537253922820204
- StevenAHeidukMRecktenwaldCVColorectal carcinogenesis: connecting K-RAS-induced transformation and CREB activity in vitro and in vivoMol Cancer Res20151381248126225934695
- DengYWangLTanSKRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancerMol Oncol201591341134725864038
- LievreABachetJBLe CorreDKRAS mutation status is predictive of response to cetuximab therapy in colorectal cancerCancer Res2006663992399516618717
- Ovarian Cancer Association ConsortiumBreast Cancer Association ConsortiumConsortium of Modifiers of BRCA1 and BRCA2Australian Ovarian Cancer Study GroupBreast Cancer Family Register, GEMO Study CollaboratorsGENICA Network; KConFab InvestigatorsNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancerGynecol Oncol20151500863-X
- LiZHPanXMHanBWA let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancerTumour Biol2013343159316323729275
- KumarMSLuJMercerKLGolubTRJacksTImpaired microRNA processing enhances cellular transformation and tumorigenesisNat Genet20073967367717401365
- JohnsonSMGrosshansHShingaraJRAS is regulated by the let-7 microRNA familyCell200512063564715766527
- CrowleyEHArenaSLambaSDi NicolantonioFBardelliATargeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levelsHum Mutat20143520821424282149